Windward Bio files for Nasdaq IPO: Its core product, an ultra-long-acting TSLP antibody, was in-licensed from Harbour BioMed.

【Answer 1】 Armstrong Technology Deep Dives Series ・Comprehensive Review of the GPRC5D Target; ・Comprehensive Review of the CD40 Target; ・Comprehensive Review of the CD47 Target; ・Comprehensive Review of Complement-Targeting Therapeutics; ・Complement-Targeting Drugs: A Key Direction for Ophthalmic Therapy; ・Comprehensive Review of the Claudin 6 Target; ・Comprehensive Review of the Claudin 18.2 Target; ・Target Popularity: An Industry-Self-Evident Truth; ・Landscape of Large-Molecule Novel Drug Development in China; ・The Criticized 'Me-Too' Approach; ・A Century of Adjuvant Development; ・A Century of Insulin Innovation; ・CUSBEA: Forty Years of Trials and Triumphs; ・Anxiety in China’s Novel Drug R&D; ・R&D Competition Among Chinese Biopharmaceutical Companies; ・Competitive Landscape of Bispecific Antibodies in China; ・Competitive Landscape of ADCs in China; ・Comprehensive Review of Bispecific Antibody Technologies in China; ・Comprehensive Review of ADC Technologies in China; ・Comprehensive Review of Ambrx Technologies; ・Comprehensive Review of Vir Biotech Technologies; ・Comprehensive Review of Immune-Onc Technologies; ・Comprehensive Review of Gracell Biotechnologies; ・Comprehensive Review of CTTQ Pharma Technologies; ・Comprehensive Review of CARsgen Therapeutics; ・Comprehensive Review of KACTUS Bio; ・Comprehensive Review of Tongyi Pharmaceuticals; ・Comprehensive Review of Biotheus Technologies; ・Comprehensive Review of Brii Biosciences; ・Comprehensive Review of Transcenta Holdings; ・Comprehensive Review of Evergrande Biotech; ・Comprehensive Review of Chinese Antibody Technologies; ・Comprehensive Review of Apexigen Technologies; ・Comprehensive Review of Apexigen Technologies 2.0; ・Comprehensive Review of Harbour BioMed Technologies; ・Comprehensive Review of RemeGen; ・Comprehensive Review of Zai Lab; ・Comprehensive Review of WuXi Biologics; ・Comprehensive Review of Hengrui Medicine; ・Comprehensive Review of Hansoh Pharmaceutical; ・Comprehensive Review of CSPC Pharmaceutical Group; ・Comprehensive Review of Genecore; ・Comprehensive Review of基石Pharma (CStone Pharmaceuticals); ・Comprehensive Review of BeiGene; ・Comprehensive Review of BeiGene (Second Edition); ・Comprehensive Review of Innovent Biologics; ・Comprehensive Review of Innovent Biologics (Second Edition); ・Comprehensive Review of Akeso; ・Comprehensive Review of Henlius; ・Comprehensive Review of Simcere Pharmaceutical; ・Comprehensive Review of Junshi Biosciences; ・Comprehensive Review of Genor Biopharma; ・Comprehensive Review of Zhidao Biopharma; ・Comprehensive Review of Daoluo Biopharma; ・Comprehensive Review of Shangjian Biopharma; ・Comprehensive Review of Kangtai Biotech; ・Comprehensive Review of Kesin Medical; ・Comprehensive Review of LianBio; ・Comprehensive Review of Momenta; ・Comprehensive Review of NGM Biopharmaceuticals; ・Comprehensive Review of Promis Biotech; ・Comprehensive Review of Promis Biotech 2.0; ・Comprehensive Review of Clover Biopharmaceuticals; ・Comprehensive Review of Betta Pharmaceuticals’ Antibody Portfolio; ・Comprehensive Review of Zelgen Biopharmaceuticals’ Antibody Portfolio; ・Comprehensive Review of Hengrui Medicine’s Antibody Portfolio; ・Comprehensive Review of Qilu Pharmaceutical’s Antibody Portfolio; ・Comprehensive Review of CSPC Pharmaceutical Group’s Antibody Portfolio; ・Comprehensive Review of Hansoh Pharmaceutical’s Antibody Portfolio; ・Comprehensive Review of Huahai Pharmaceutical’s Antibody Portfolio; ・Comprehensive Review of Kelun Pharmaceuticals’ Antibody Portfolio; ・Comprehensive Review of Bio-Thera Solutions; ・Comprehensive Review of Fennex Therapeutics.

From seller to investor: Chinese pharmaceutical companies are shifting roles within NewCo arrangements.

【Answer 2】 Another round of financing—nothing unusual. What merits attention, however, is that Harbour BioMed has conspicuously appeared on the investor list. It is no longer novel for Chinese pharma companies to passively hold equity in the buyer as part of a NewCo collaboration. Yet it is uncommon—indeed unprecedented in prior NewCo deals—for them to follow up, just one year later, by injecting substantial cash directly into the buyer’s balance sheet. Subsequently, Windward Bio’s announcement of successful Phase II clinical trial results clarified the rationale behind Harbour BioMed’s move. Data showed that, following a single dose administered to 147 patients with uncontrolled moderate-to-severe asthma, all three key endpoints—FEV1, FeNO, and blood eosinophil count—improved significantly at Week 24, achieving statistical significance. This validates the ultra-long-acting narrative for HBM9378: therapeutic efficacy remains evident 24 weeks after a single administration. More importantly, according to official statements, HBM9378’s peak efficacy emerges as early as Week 2—meaning its maximal effect can persist for up to 22 weeks. Compared to the approved TSLP antibody tezepelumab—which requires monthly dosing—HBM9378 demonstrates unprecedented commercial potential in terms of patient adherence. Precisely for this reason, Harbour BioMed is no longer content merely fulfilling its role as an asset supplier to realize platform value; instead, it is proactively seeking leadership in the capital-market revaluation of its assets. Coinciding with HBM9378’s Phase II triumph, Harbour BioMed’s fully human antibody transgenic mouse platform—Harbour Mice®—has once again gained global validation. Almost simultaneously, another clinical asset derived from this platform—the second-generation Fc-enhanced CTLA-4 antibody HBM4003—is poised to embark on its own global validation journey. This time, Harbour BioMed navigates the NewCo model with remarkable fluency. In February 2026, a venture capital firm established Solstice Oncology—and immediately incorporated Harbour BioMed’s HBM4003 into the company’s pipeline. In this transaction, Harbour BioMed secured over USD 105 million in upfront consideration—including USD 50 million in equity—and up to USD 1.1 billion in milestone payments. Just seven months later, Solstice Oncology raised a USD 225 million Series A round led by RA Capital Management, with participation from Canaan Partners, Forbion, and other investors. Meanwhile, Solstice registered a global Phase II study on ClinicalTrials.gov evaluating pembrolizumab plus HBM4003 as neoadjuvant therapy for pMMR/MSS Stage II–III colon cancer. Previously, Harbour BioMed’s China-based Phase II data demonstrated that HBM4003 combined with tislelizumab achieved a 34.8% objective response rate (ORR) and a median progression-free survival (mPFS) of 4.2 months in later-line treatment of MSS metastatic colorectal cancer. Now, Solstice’s global Phase II study deliberately bypasses later-line settings and opts for neoadjuvant therapy—to better leverage HBM4003’s advantages of short half-life, high tissue penetration, and potent Treg depletion. Within the narrow surgical window, this strategy aims to strike an optimal balance between efficacy and safety.

Novo-backed Windward Bio Targets $1 Billion Valuation in US IPO

16 hours ago

Swiss drug developer Windward Bio Group targets a $1 billion valuation in its US IPO, raising $185.3 million for antibody medicines treating respiratory and dermatologic diseases. The offering is backed by Novo Holdings and includes investment from Sanofi.

reuters

2026-10-23

Swiss drug developer Windward Bio files for US IPO

2026-11-09

Novo-backed Windward Bio Targets $1 Billion Valuation in US IPO

Novo-backed Windward Bio Targets $1 Billion Valuation in US IPO

FAQ